COGT Stock Earnings Cogent Biosciences Misses EPS for Q2 2024 - MSN
| COGT Stock | USD 9.63 0.44 4.79% |
Slightly above 71 percent of all Cogent Biosciences' private investors are curious in acquiring. The analysis of the overall investor sentiment regarding Cogent Biosciences suggests that a large number of traders are confidant. Cogent Biosciences' investing sentiment can be driven by a variety of factors including economic data, Cogent Biosciences' earnings reports, geopolitical events, and overall market trends.
Cogent |
COGT Stock Earnings Cogent Biosciences Misses EPS for Q2 2024 MSN
Read at news.google.com
 |
Cogent Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cogent Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cogent Biosciences Fundamental Analysis
We analyze Cogent Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cogent Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cogent Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Cogent Biosciences is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Cogent Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cogent Biosciences stock to make a market-neutral strategy. Peer analysis of Cogent Biosciences could also be used in its relative valuation, which is a method of valuing Cogent Biosciences by comparing valuation metrics with similar companies.
Peers
Cogent Biosciences Related Equities
| VTYX | Ventyx Biosciences | 23.30 | ||||
| OLMA | Olema Pharmaceuticals | 9.09 | ||||
| MRSN | Mersana Therapeutics | 8.50 | ||||
| ANAB | AnaptysBio | 4.77 | ||||
| CGEM | Cullinan Oncology | 1.83 | ||||
| KROS | Keros Therapeutics | 1.43 | ||||
| KNSA | Kiniksa Pharmaceuticals | 1.10 | ||||
| MGTX | MeiraGTx Holdings | 0.95 | ||||
| IDYA | Ideaya Biosciences | 0.90 | ||||
| VRNA | Verona Pharma | 0.40 | ||||
| ZNTL | Zentalis Pharmaceuticals | 0.57 | ||||
| KALV | Kalvista Pharmaceuticals | 0.89 | ||||
| SANA | Sana Biotechnology | 1.21 | ||||
| SNDX | Syndax Pharmaceuticals | 1.37 | ||||
| PTGX | Protagonist Therapeutics | 1.54 | ||||
| KURA | Kura Oncology | 1.92 | ||||
| LRMR | Larimar Therapeutics | 2.37 |
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.